SCPX:NYE-Scorpius Holdings Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.8071

Change

0.00 (0.00)%

Market Cap

USD 2.52M

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina. Address: 627 Davis Drive, Morrisville, NC, United States, 27560

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 609.93B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 1.03B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B

ETFs Containing SCPX

XSD SPDR® S&P Semiconductor .. 4.28 % 0.35 %

N/A

N/A
PSI Invesco Dynamic Semicondu.. 3.17 % 0.58 %

N/A

N/A
XITK SPDR® FactSet Innovative.. 2.07 % 0.45 %

N/A

USD 0.09B
SHLD:LSE iShares IV Public Limited.. 1.77 % 0.00 %

N/A

N/A
DXSN:F Xtrackers - ShortDAX Dail.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.52M 7% C- 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector